What are you looking for?
Start main content



The large-scale international study on “Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer” shows Alectinib, a second-generation ALK inhibitor, to be twice as effective and efficient as Crizotinib, the current standard treatment for ALK-positive lung cancer. Not only is the new drug more potent with fewer side effects, but it is also 70% more effective in the prevention of brain metastasis.
Prof Tony Mok, the senior author who led the research, recently presented the findings at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. These new findings are most significant in that they will likely make Alectinib the new standard of care for ALK-positive patients.


tony mak


View the full article: